A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Tanezumab (Primary)
- Indications Osteoarthritis; Pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 03 Aug 2017 Planned End Date changed from 1 Jun 2018 to 7 Jun 2018.
- 03 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 21 Dec 2017.
- 27 Jul 2017 Planned primary completion date changed from 20 Dec 2017 to 1 Dec 2017.